Springtime in Washington, D.C., is synonymous with cherry blossom season, when the thousands of cherry blossom trees gifted ...

Daiichi Sankyo used the National Cherry Blossom Festival in Washington, D.C. as a platform to raise awareness about its oncology goals.

Daiichi Sankyo has a 12 month low of $20.92 and a 12 month high of $42.48. The company has a current ratio of 2.77, a quick ratio of 2.11 and a debt-to-equity ratio of 0.06.

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive ...

Daiichi Sankyo has finalised the acquisition of intellectual property rights for gatipotuzumab, an anti-tumour-associated mucin-1 (TA-MUC1) antibody, from Glycotope for $132.5m. The gatipotuzumab ...

Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...

Jefferies analyst Stephen Barker maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) today and set a price target of ...

The Delhi High Court is reviewing RHC Healthcare's challenge to the 'Fortis' trademark sale to Fortis Healthcare, alleging ...

The Delhi High Court is reviewing the sale of the Fortis trademark. RHC Healthcare challenges the sale price to Fortis ...

Daiichi Sankyo Company, Limited leads in ADC tech with Enhertu, strong partnerships, revenue growth, and global market leadership. Click to know more on why DSNKY is a Buy.

SEATTLE, April 15, 2025 /PRNewswire/ -- Wayfinder Biosciences, a biotechnology company targeting RNA with small molecules, announced today a collaboration with Daiichi Sankyo focused on a key ...

TOKYO & MUNICH, April 08, 2025--DATROWAY® (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of adult patients with unresectable or metastatic hormone ...